ReviewCurrent HIV/AIDS reports2022
Metabolic Consequences of Antiretroviral Therapy.
Review in Current HIV/AIDS reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prevalence of cardiometabolic diseases among ART-naïve people with HIV: A global systematic review and meta-analysis.HIV medicine · 2026Pooled it
- Diabetes risk in HIV infection and antiretroviral therapy: A systematic review and meta-analysis of prospective cohort evidence.HIV medicine · 2026Pooled it
- Dysregulated Metabolism in People Living With HIV in the Modern ART-Era: A Systematic Review of Targeted Metabolomics Studies.Reviews in medical virology · 2026Pooled it
- Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.The Journal of antimicrobial chemotherapy · 2024Trial
- Major Depressive Episodes and Psychiatric Symptoms Among HIV Controllers Compared With Antiretroviral-Treated People Living With HIV.Open forum infectious diseases · 2026Article
- Real-World Multicenter Study on the Effectiveness of Dolutegravir Plus Lamivudine in Treatment-Naive People Living with HIV with Baseline HIV-1 RNA > 500,000 Copies/mL.Infectious diseases and therapy · 2026Article
- The evaluation of an HIV-PrEP drug on the vascular health outcomes in a diet-induced prediabetes condition rat model.Scientific reports · 2026Article
- Metabolic syndrome and its risk factors among adults living with HIV receiving antiretroviral therapy in Zambia: an ambidirectional cohort study.Scientific reports · 2026Article
- Long-Term Effectiveness and Tolerability of Dolutegravir/Lamivudine in Korea: A 3-Year Follow Up Study.Infection & chemotherapy · 2026Article
- Novel effects of reverse transcriptase inhibitor supplementation in skeletal muscle of old mice.Physiological genomics · 2025Article
- Changes in the lipid profile in people with HIV after one year of antiretroviral therapy - the significance of immune parameters.IJID regions · 2025Article
- Efficacy and safety of dolutegravir plus lamivudine for patients with late presentation of HIV-1 infection: a retrospective real-world cohort study in Southwest China.Frontiers in medicine · 2025Article
- Plasma Lipidomic Profiles in cART-Treated Adolescents with Perinatally Acquired HIV Compared to Matched Controls.Viruses · 2024Article
- Metabolic syndrome among people living with HIV in Ethiopia: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2023Review
- Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND).Current HIV/AIDS reports · 2022Review
- Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients.Infection & chemotherapy · 2022Review
- Sociodemographic and Clinical Predictors of Weight Gain During the First Year of Antiretroviral Therapy among Adults Living With HIV in Urban Tanzania.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewThis review reports on published studies describing metabolic changes associated with antiretroviral therapy (ART) to treat HIV disease including a historical perspective of earlier ART agents, but with the main focus on newer ART agents currently in use. RECENT
findingsStudies from different countries around the world have shown that integrase inhibitor (INSTI)-based regimens as well as tenofovir alafenamide (TAF) are associated with weight gain, with women and people of black race at especially high risk. Some studies preliminarily suggest worsened metabolic outcomes associated with this weight gain including adverse effects on glucose homeostasis. Antiretroviral therapy can affect weight, adipose tissue, glucose, and lipids. As obesity is prevalent and increasing among people with HIV, awareness of risk factors for weight gain, including the ART medications associated with greater weight gain, are needed in order to inform prevention efforts. Further research is needed to better understand the long-term health consequences of INSTI- and TAF-associated weight increases.
Indexed as
Identifiers
35299263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.